Startup Licenses Technology Developed At BYU

A firm which has licensed technology developed at the Utah Artificial Heart Institute has scored funding for its efforts to bring its products to market. Aggredyne, which says it is developing biomedical diagnostics products for measuring platelet function, said today that it has raised $3M in a Series A funding round for commercializing the technology, which it licensed from Brigham Young University. Source of the funding was not announced. Aggredyne is based in Houston, Texas. Aggredyne said the technology had previously been licensed to Thrombodyne in Salt Lake City, and then to ThromboVision, in Texas; the firm did not explain how the technology eventually ended up at the firm.